- Home
- DTSQ vs CRBP Comparison
DTSQ vs CRBP Comparison
Compare DTSQ & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- CRBP
- Stock Information
- Founded
- DTSQ 2022
- CRBP 2009
- Country
- DTSQ United States
- CRBP United States
- Employees
- DTSQ N/A
- CRBP N/A
- Industry
- DTSQ
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- DTSQ
- CRBP Health Care
- Exchange
- DTSQ NYSE
- CRBP Nasdaq
- Market Cap
- DTSQ 90.9M
- CRBP 73.4M
- IPO Year
- DTSQ 2024
- CRBP N/A
- Fundamental
- Price
- DTSQ N/A
- CRBP $6.03
- Analyst Decision
- DTSQ
- CRBP Strong Buy
- Analyst Count
- DTSQ 0
- CRBP 10
- Target Price
- DTSQ N/A
- CRBP $60.89
- AVG Volume (30 Days)
- DTSQ 13.0K
- CRBP 207.2K
- Earning Date
- DTSQ 01-01-0001
- CRBP 05-06-2025
- Dividend Yield
- DTSQ N/A
- CRBP N/A
- EPS Growth
- DTSQ N/A
- CRBP N/A
- EPS
- DTSQ 0.25
- CRBP N/A
- Revenue
- DTSQ N/A
- CRBP N/A
- Revenue This Year
- DTSQ N/A
- CRBP N/A
- Revenue Next Year
- DTSQ N/A
- CRBP $150.00
- P/E Ratio
- DTSQ $40.47
- CRBP N/A
- Revenue Growth
- DTSQ N/A
- CRBP N/A
- 52 Week Low
- DTSQ $9.96
- CRBP $4.64
- 52 Week High
- DTSQ $10.37
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- CRBP 49.07
- Support Level
- DTSQ N/A
- CRBP $5.68
- Resistance Level
- DTSQ N/A
- CRBP $6.29
- Average True Range (ATR)
- DTSQ 0.00
- CRBP 0.46
- MACD
- DTSQ 0.00
- CRBP 0.19
- Stochastic Oscillator
- DTSQ 0.00
- CRBP 84.24
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.